These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 11193894

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.
    Int J Cancer; 2004 Jan 01; 108(1):146-51. PubMed ID: 14618629
    [Abstract] [Full Text] [Related]

  • 4. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL, Zunino F.
    Cancer Res; 2001 Aug 15; 61(16):6034-7. PubMed ID: 11507048
    [Abstract] [Full Text] [Related]

  • 5. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 6. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH.
    J Natl Cancer Inst; 2000 Oct 18; 92(20):1651-6. PubMed ID: 11036110
    [Abstract] [Full Text] [Related]

  • 7. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
    Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC.
    Biochem Pharmacol; 2000 Sep 15; 60(6):831-7. PubMed ID: 10930538
    [Abstract] [Full Text] [Related]

  • 8. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
    Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S.
    Cancer Res; 2001 Apr 01; 61(7):2827-32. PubMed ID: 11306452
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S.
    Clin Cancer Res; 2003 Aug 01; 9(8):3052-7. PubMed ID: 12912956
    [Abstract] [Full Text] [Related]

  • 11. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
    Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH.
    Clin Cancer Res; 2001 Apr 01; 7(4):935-41. PubMed ID: 11309344
    [Abstract] [Full Text] [Related]

  • 12. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, Kodaira H, Takahashi H, Aiyama R, Matsuzaki T, Yagi N, Sugimoto Y.
    Mol Cancer Ther; 2011 Jul 01; 10(7):1252-63. PubMed ID: 21566063
    [Abstract] [Full Text] [Related]

  • 13. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q.
    Cancer Chemother Pharmacol; 2006 Sep 01; 58(3):374-83. PubMed ID: 16404634
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y, Lee SH, Sinko PJ.
    Eur J Pharm Sci; 2006 Oct 01; 29(2):102-10. PubMed ID: 16844360
    [Abstract] [Full Text] [Related]

  • 15. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
    Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y.
    Jpn J Cancer Res; 2002 Mar 01; 93(3):231-5. PubMed ID: 11927002
    [Abstract] [Full Text] [Related]

  • 16. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M, Iwahana M, Mitsui I, Minami M, Imagawa S, Tohgo A, Ejima A.
    Anticancer Drugs; 2000 Jun 01; 11(5):353-62. PubMed ID: 10912951
    [Abstract] [Full Text] [Related]

  • 17. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
    Van Hattum AH, Schlüper HM, Hausheer FH, Pinedo HM, Boven E.
    Int J Cancer; 2002 Jul 01; 100(1):22-9. PubMed ID: 12115582
    [Abstract] [Full Text] [Related]

  • 18. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.
    Oncol Rep; 2012 Jun 01; 27(6):1703-9. PubMed ID: 22426819
    [Abstract] [Full Text] [Related]

  • 19. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y.
    Mol Cancer Ther; 2002 Jun 01; 1(8):611-6. PubMed ID: 12479221
    [Abstract] [Full Text] [Related]

  • 20. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH.
    Cancer Res; 2001 Jan 15; 61(2):739-48. PubMed ID: 11212277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.